Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA To Review Pfizer’s Abrilada For Humira Interchangeability

Adalimumab Biosimilar Is Set For US Launch In July 2023

Mar 03 2022

• By Chloe Kent

Signpost two directions — Pfizer is seeking an interchangeable designation for its adalimumab biosimilar • Source: Frannyanne / Alamy Stock Photo

Related Content

Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

Feb 25 2021

Coherus Distances Itself From Biosimilar Interchangeability

May 07 2021

Reed Sets Out Priorities For US Biosimilars Forum

Feb 16 2022

Medscape To Develop FDA Biosimilars Educational Program

Feb 21 2022

Humira One Year Out: The Largest LOE Event In US Pharma History

Mar 02 2022

Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023

Oct 29 2021

First Interchangeable Humira Biosimilar Approved In US

Oct 18 2021

Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait

Nov 18 2019

Related Companies

Pfizer Inc.

Additional Topics

United States Biosimilars Approvals Regulation BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.